Compare Biogen Inc (BIIB) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Xylem, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Xylem, Inc. trades at $121.4 (market cap $28.76B). The key difference: Biogen Inc and Xylem, Inc. are close in size by market cap, and Xylem, Inc. pays a 1.4% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | XYL | |
|---|---|---|
Market Cap | $30.13B | $28.76B |
Sector | Health | Industrials |
52-Week High | $216.63 | $152.95 |
52-Week Low | $128.93 | $106.34 |
Enterprise Value | $37.20B | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Xylem (XYL) trades at $121.87, up 0.56% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company's fundamentals show robust revenue growth, expanding margins, and healthy cash flow, supported by strategic acquisitions like Cornell Pump and Roper Pump to bolster its industrial water technology presence. Analyst consensus is mixed but leans positive, with a $150.43 price target implying significant upside.
Outlook remains favorable due to secular demand in water infrastructure and AI-driven data centers, though risks include execution on acquisitions and economic sensitivity. The stock offers growth potential from margin expansion and digital water solutions, but investors should monitor integration challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
